Improved therapeutic strategies are in urgent need for better control and eradication of tuberculosis. In this editorial, the authors evaluate interleukin-37 as a new molecular target for the therapy of tuberculosis.
Browsing: Basic > Pre-clinical Trials
Researchers have demonstrated an imaging technique utilizing PET, which allows non-invasive and real-time monitoring of dengue infection in mouse models.
Research presented at ASM Microbe has reported a Zika vaccine based on the NS1 protein can induce protective immunity in mouse models after a single dose.
A team from the Scripps Research Institute have determined the structure of clade C HIV-1 envelope glycoprotein, an immunogen that could be utilized in a future HIV vaccine.
Development of protein vaccine to prevent congenital infection is a public health priority, this research investigates the design of a mucosal synthetic pathogen as a vaccine strategy against congenital toxoplasmosis.
The recurring resistance of the malaria parasite to many drugs compels the design of innovative chemical entities in antimalarial research. In light of this, the authors discuss thiaheterocyclic hHDAC6 inhibitors as potentially powerful novel antimalarials.
John-Arne Røttingen discusses his role as founding CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) and his thoughts on the importance of developing new vaccines for emerging threats.
In new research, the first live-attenuated Zika vaccine has been demonstrated to protected mice against the virus after a single dose.
Take a look at our new infographic, developed for World Tuberculosis Day, which explores the facts about current TB burden, the issues around drug resistance, and research and development moving forwards.